References

Newman B, Mu H, Butler LM, Millikan RC, Moorman PG, King MC. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women . JAMA 1998;279:915.

Lane-Clayton J. A further report on cancer of the breast, with special reference to its associated antecedent conditions. Reports of the Ministry of Health. London: His Majesty's Stationary Office, 1926–1932.

Wasink W. Cancer et heredite. Genetika 1935;17:103.

Penrose L, MacKenzie HJ, Karn MNA. Genetical study of human mammary cancer. Ann Eugenics 1948;14:234.

Anderson V, Goodman K, Reed S. Variables related to human breast cancer. Minneapolis, MN: University of Minnesota Press, 1950.

Adami HO, Hansen J, Jung B, Rimsten A. Characteristics of familial breast cancer in Sweden-absence of relation to age and unilateral versus bilateral disease. Cancer 1981;48:1688.

Lubin JH, Burns PE, Blot WJ, et al. Risk factors for breast cancer in women in northern Alberta, Canada, as related to age at diagnosis. J Natl Cancer Inst 1982;68:211.

Bain C, Speizer FE, Rosner B, Belanger C, Hennekens CH. Family history of breast cancer as a risk indicator for the disease. Am J Epidemiol 1980;111:301.

Anderson DE. Some characteristics of familial breast cancer. Cancer 1971;28:1500.

Anderson DE. Breast cancer in families. Cancer 1977;140[Suppl 4]: 1855.

Williams WR, Anderson DE. Genetic epidemiology of breast cancer: segregation analysis of 200 Danish pedigrees. Genet Epidemiol 1984;11(l):7.

Newman B, Austin MA, Lee M, King MC. Inheritance of human breast cancer: evidence for autosomal dominant transmission in high-risk families. Proc Natl Acad Sci U S A 1988;85:3044.

Amos Cl, Goldstein AM, Harris EL. Familiality of breast cancer and socioeconomic status in blacks. Cancer Res 1991;51:1793.

Schatzkin A, Palmer JR, Rosenberg L, et al. Risk factors for breast cancer in black women. J Natl Cancer Inst 1987;78:213.

Bondy M. Ethnic differences in familial breast cancer. Proc Am Assoc Cancer Res 1991;[Suppl]:Al316.

Siraganian PA, LeNine PR, Madigan P, Mulvihill JJ. Familial breast cancer in black Americans. Cancer 1987;60:1657.

Chamberlain JS, Boehnke M, Frank TS, et al. BRCA1 maps proximal to DI 7S579 on chromosome 17q2l by genetic analysis. Am J Hum Genet 1993;52:792.

Arena J, Smith S, Plewinska M, et al. BRCA1 mutations in African-American women. Am J Hum Genet 1996;59[Suppl]:A34.

Gao Q, Neuhausen S, Cummings S, Luce M, Olopade OI. Recurrent germ-line BRCA1 mutations in extended African American families with early-onset breast cancer [Letter]. Am J Hum Genet 1997;160:1233.

Weiss KM, Chakraborty R, Smouse PE, Buchanan AV, Strong LC. Familial aggregation of cancer in Laredo, Texas: a generally low-risk Mexican-American population. Genet Epidemiol 1986;3:121.

Osorio A, Robledo M, San Roinan JM, et al. Mutation analysis of the BRCA2 gene in breast/ovarian cancer Spanish families: identification of two new mutations. Cancer Lett 1997;1121:115.

Osorio A, Robledo M, Albertos J, et al. Molecular analysis of the six most recurrent mutations in the BRCA1 gene in 87 Spanish breast/ovarian cancer families. Cancer Lett 1998;123:153.

Garcia-Patino E, Gomendio B, Provencio M, et al. Germline BRCA1 mutations in women with sporadic breast cancer: clinical correlations. J Clin Oncol 1998;16(l):115.

Garcia-Patino E, Gomendio B, Silva JM, et al. BRCA1 mutations in patients with familial risk of breast cancer [Letter]. Acta Oncol 1998;37:299.

Kato I, Miura S, Kasurmi F, et al. A case-control study of breast cancer among Japanese women: with special reference to family history and reproductive and dietary factors. Breast Cancer Res Treat 1992;24(l):51.

Katagiri T, Emi M, Ito I, et al. Mutations in the BRCA1 gene in Japanese breast cancer patients. Hum Mutat 1996;7:334.

Takano M, Aida H, Tsuneki I, et al. Mutational analysis of BRCA1 gene in ovarian and breast-ovarian cancer families in Japan. Jpn J Cancer Res 1997;88:407.

Inoue R, Ushijima T, Fukutomi T, et al. BRCA2 germ-line mutations in Japanese breast cancer families. Int J Cancer 1997;74:199.

Inoue R, Fulcutomi T, Ushijima T, Matsumoto Y, Sugimura T, Nagao M. Germline mutation of BRCA1 in Japanese breast cancer families. Cancer Res 1995;55:3521.

Zidan J, Diab M, Robinson E. [Familial breast cancer in Arabs]. Harefuah 1992;122:767–769, 819.

Sattin RW, Rubin GL, Webster LA, et al. Family history and the risk of breast cancer. JAMA 1985;253:1908.

Claus EB, Risch N, Thompson AD. Genetic analysis of breast cancer in the Cancer and Steroid Hormone Study. Am J Hum Genet 1991;48:232.

Claus EB, Schildkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer 1996;77:18.

Fitzgerald MG, MacDonald DJ, Krainer M, et al. Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer . N Engl J Med 1996;334:143.

Couch FJ, DeShano ML, Blackwood MA, et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer . N Engl J Med 1997;336:1409.

Krainer M, Silva-Arrieta S, Fitzgerald MG, et al. Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer . N Engl J Med 1997;336:1416.

Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 1971;68:820.

Hall JM, Lee MK, Newman B, et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990;250(4988):1684.

Narod SA, Feunteun J, Lynch HT, et al. Familial breast-ovarian cancer locus on chromosome 17ql2-q23 . Lancet 1991;338(8759):82.

Easton DF, Bishop DT, Ford D, Crockford GP. Genetic linkage analysis in familial breast and ovarian cancer results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1993;52:678.

Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401.

Whittemore AS, Gong G, Itnyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer. Am J Hum Genet 1997;160:496.

Stoppa-Lyonnet D, Laurent-Puig P, Essioux L, et al. BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic. Institut Curie Breast Cancer Group. Am J Hum Genet 1997;60:1021.

Shattuck-Eidens D, Oliphant A, McClure M, et al. BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA 1997;278:1242.

Frank TS, Manley SA, Olopade OI, et al. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol 1998;16:2417.

Bergthorsson JT, Johannsdottir J, Jonasdottir A, et al. Chromosome imbalance at the 3pl4 region in human breast tumours: high frequency in patients with inherited predisposition due to BRCA2. Eur J Cancer 1998;34(l):142.

Huusko P, Paakkonen K, Launonen V, et al. Evidence of founder mutations in Finnish BRCA1 and BRCA2 families [Letter]. Am J Hum Genet 1998;62:1544.

Ramus SJ, Kote-Jarai Z, Friedman LS, et al. Analysis of BRCA1 and BRCA2 mutations in Hungarian families with breast or breast-ovarian cancer [Letter]. Am J Hum Genet 1997;60:1242.

Gayther SA, Mangion J, Russell P, et al. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet 1997;15(l):103.

Petrij-Bosch A, Peelen T, van Vliet M, et al. BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients [Published erratum appears in Nat Genet 1997;17:503]. Nat Genet 1997;17:341.

Levy-Lahad E, Catane R, Eisenberg S, et al. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet 1997;160:1059.

Johannsson O, Ostermever EA, Hakansson S, et al. Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden. Am J Hum Genet 1996;158:441.

Dorum A, Moller P, Kamsteeg EJ, et al. A BRCA1 founder mutation, identified with haplotype analysis, allowing genotype/phenotype determination and predictive testing. Eur J Cancer 1997;33:2390.

Szabo CI, King MC. Population genetics of BRCA1 and BRCA2 [Editorial; comment]. Am J Hum Genet 1997;60:1013.

Thorlacius S, Olafsdottir G, Tryggvadottir L, et al. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet 1996;13(l):117.

Couch FJ, Weber BL. Mutations and polymorphisms in the familial early-onset breast cancer (BRCA1) gene. Hum Mutat 1996;8(l):8.

Tonin P, Serova O, Lenoir G, et al. BRCA1 mutations in Ashkenazi Jewish women [Letter]. Am J Hum Genet 1995;57(l):189.

Struewing JP, Abehovich D, Peretz T, et al. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 1995;11:198.

Gayther SA, Warren W, Mazoyer S, et al. Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet 1995;11:428.

Offit K, Gilewski T, McGuire P, et al. Germline BRCA1 185detAG mutations in Jewish women with breast cancer. Lancet 1996;347(9016):1643.

Muto MG, Cramer DW, Tangir J, Berkowitz R, Mok S. Frequency of the BRCA1 185delAG mutation among Jewish women with ovarian cancer and matched population controls. Cancer Res 1996;56:1250.

Abeliovich D, Kaduri L, Lerer I, et al. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 1997;60:505.

Berman DB, Wagner-Costalas J, Schultz DC, Lynch HT, Daly M, Godwin AK. Two distinct origins of a common BRCA1 mutation in breast-ovarian cancer families: a genetic study of 15 185delAG-mutation kindreds. Am J Hum Genet 1996;58:1166.

Arason A, Barkardottir RB, Eglisson V. Linkage analysis of chromosome 17q markers and breast-ovarian cancer in Icelandic families, and possible relationship to prostatic cancer. Am J Hum Genet 1993; 52:711.

Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994;343(8899):692.

Lynch HT, Marcus J, Watson P, Page D. Distinctive clinicopathologic features of BRCA1-linked hereditary breast cancer. Proc Am Soc Clin Oncol 1994;13:56.

Anonymous. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium. Lancet 1997;349(9064):1505.

Marcus JN, Watson P, Page DL, et al. Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 1996;77:697.

Karp SE, Tonin PN, Begin LR, et al. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. Cancer 1997;80:435.

Robson M, Rajan P, Rosen PP, et al. BRCA-associated breast cancer: absence of a characteristic immunophenotype. Cancer Res 1998; 58:1839.

Wagner TM, Moslinger RA, Muhr D, et al. BRCA1-related breast cancer in Austrian breast and ovarian cancer families: specific BRCA1 mutations and pathological characteristics. Int J Cancer 1998;77:354.

Eisinger F, Stoppa-Lyonnet D, Longy M, et al. Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. Cancer Res 1996;56:471.

Tirkkonen M, Johannsson O, Agnarsson BA, et al. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res 1997;57:1222.

Tapper J, Sarantaus L, Vahteristo P, et al. Genetic changes in inherited and sporadic ovarian carcinomas by comparative genomic hybridization: extensive similarity except for a difference at chromosome 2q24-q32. Cancer Res 1998;58:2715.

Johannsson OT, Ranstam J, Borg A, Olsson H. Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J Clin Oncol 1998;16:397.

Verhoog LC, Brekelmans CT, Seynaeve C, et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 1998;351(9099):316.

Foulkes WD, Wong N, Rozen F, Brunet JS, Narod SA. Survival of patients with breast cancer and BRCA1 mutations [Letter]. Lancet 1998;351(9112):1359.

Merajver SD, Pham TM, Caduff RF, et al. Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. Nat Genet 1995;9:439.

Hosking L, Trowsdate J, Nicolai H, et al. A somatic BRCA1 mutation in an ovarian tumour [Letter]. Nat Genet 1995;9:343.

Takahashi H, Behbakht K, McGovern PE, et al. Mutation analysis of the BRCA1 gene in ovarian cancers. Cancer Res 1995;55:2998.

Matsushima M, Kobayashi K, Emi M, et al. Mutation analysis of the BRCA1 gene in 76 Japanese ovarian cancer patients: four germline mutations, but no evidence of somatic mutation. Hum Mol Genet 1995;4:1953.

Boyd M, Harris F, McFarlane R, Davidson HR, Black DM. A human BRCA1 gene knockout [Letter]. Nature 1995;375(6532):541.

Tsongalis GJ, Linfert DR, Johnson RC, Ackroyd R, Berman MM, Ricci A Jr. Double heterozygosity for mutations in the BRCA1 and BRCA2 genes in a breast cancer patient. Arch Pathol Lab Med 1998;1122:548.

Holt JT, Thompson ME, Szabo C, et al. Growth retardation and tumour inhibition by BRCA1. Nat Genet 1996;12:298.

Sobol H, Stoppa-Lyonnet D, Bressac-de-Paillerets B, et al. Truncation at conserved terminal regions of BRCA1 protein is associated with highly proliferating hereditary breast cancers. Cancer Res 1996;56:3216.

Chen Y, Chen CF, Riley DJ, et al. Aberrant subcellular localization of BRCA1 in breast cancer. Science 1995;270(5237):789.

Scully R, Ganesan S, Brown M, et al. Localization of BRCA1 in human breast and ovarian cancer cells. Science 1996;272:122.

Thakur S, Zhang HB, Peng Y, et al. Localization of BRCA1 and a splice variant identifies the nuclear localization signal. Mol Cell Biol 1997;17(l):444.

Wilson CA, Payton MN, Elliott GS, et al. Differential subcellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1-deltal lb. Oncogene 1997;14:1.

Jensen RA, Thompson ME, Jetton TL, et al. BRCA1 secreted and exhibits properties of a granin. Nat Genet 1996;12:303.

Wilson CA, Payton MN, Pekar SK, et al. BRCA1 protein products: antibody specificity. Nat Genet 1996;13:264.

Roehm PC, Berg JM. Sequential metal binding by the RING finger domain of BRCA1. Biochemistry 1997;36:10240.

Jensen DE, Proctor M, Marquis ST, et al. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene 1998;16:1097.

Wu LC, Wang ZW, Tsan JT, et al. Identification of a RING protein that can interact in vivo with the BRCA1 gene product. Nat Genet 1996;14:430.

Scully R, Anderson SF, Chao DM, et al. BRCA1 is a component of the RNA polymerase 11 holoenzyme. Proc Natl Acad Sci U S A 1997;94:5605.

Cui JQ, Shao N, Chai Y, Wang K, Reddy ES, Pao VN. BRCA1 splice variants BRCA1a and BRCA1b associate with CBP co-activator. Oncol Rep 1998;5:591.

Chapman MS, Verma IM. Transcriptional activation by BRCA1 [Letter; comment]. Nature 1996;382:678.

Monteiro AN, August A, Hanafusa H. Evidence for a transcriptional activation function of BRCA1 C-terminal region. Proc Natl Acad Sci U S A 1996;93:13595.

Zhang H, Somasundaram K, Peng Y, et al. BRCA1 physically associates with p53 and stimulates its transcriptional activity. Oncogene 1998;16:1713.

Ouchi T, Monteiro AN, August A, Aaronson SA, Hanafusa H. BRCA1 regulates p53-dependent gene expression. Proc Natl Acad Sci U S A 1998;95:2302.

Somasundaram K, Zhang K, Zeng YX, et al. Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1. Nature 1997;389:187.

Marquis ST, Rajan JV, Wynshaw-Boris A, et al. The developmental pattern of Brca1 expression implies a role in differentiation of the breast and other tissues. Nat Genet 1995;111:17.

Gowen LC, Johnson BL, Latour AM, Sulik KK, Koller BH. Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities. Nat Genet 1996;12:191.

Hakem R, de la Pompa JL, Strard C, et al. The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. Cell 1996;85:1009.

Liu CY, Flesken-Nikitin A, Li S, Zeng Y, Lee WH. Inactivation of the mouse Brca1 gene leads to failure in the morphogenesis of the egg cylinder in early postimplantation development. Genes Dev 1996;10:1835.

Ludwig T, Chapman DL, Papaioannou VE, Efstratiadis A. Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brea2/p53 nullizygous embryos. Genes Dev 1997;11:1226.

Gudas JM, Nguyen H, Li T, Cowan KE. Hormone-dependent regulation of BRCA1 in human breast cancer cells. Cancer Res 1995;55:4561.

Chen Y, Farmer AA, Chen CF, Jones DC, Chen PL, Lee NVH. BRCA1 is a 220-kDa nuclear phosphoprotein that is expressed and phosphorylated in a cell cycle-dependent manner [Published erratum appears in Cancer Res 1996;1156:4074]. Cancer Res 1996;56: 3168.

Scully R, Chen J, Plug A, et al. Association of BRCA1 with Rad5l in mitotic and meiotic cells. Cell 1997;88:265.

Chen J, Silver D, Walpita D, et al. Stable interaction between products of BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. Molecular Cell 1998;2:317.

Shinohara A, Ogawa H, Ogawa T. Rad51 protein involved in repair and recombination in S. cermislae is a RecA-like protein [Published erratum appears in Cell 1992;71]. Cell 1992;69:457.

Scully R, Chen J, Ochs RL, et al. Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell 1997;90:425.

Fan S, Twu NF, Wang JA, et al. Down-regulation of BRCA1 and BRCA2 in human ovarian cancer cells exposed to adriamycin and ultraviolet radiation. Int J Cancer 1998;77:600.

Husain A, He G, Venkatraman ES, Spriggs DR. BRCA1 up-regulation is associated with repair-mediated resistance to cis-diaminedichloroplatinum (II). Cancer Res 1998;58:1120.

Gowen LC, Avrutskaya AV, Latour AM, Koller BH, Leadon SA. BRCA1 required for transcription-coupled repair of oxidative DNA damage. Science 1998;281:1009.

Wooster R, Neuhausen SL, Mangion J, et al. Location of a breast cancer susceptibility gene, BRCA2, to chromosome 13ql2-13. Science 1994;265:2088.

Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378:789.

Tavtigian SV, Simard J, Rommens J, et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet 1996;12:333.

Hakansson S, Johannsson O, Johansson U, et al. Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer. Am J Hum Genet 1997;60:1068.

Couch FJ, Farid LM, DeShano ML, et al. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet 1996;13:123.

Schubert EL, Lee MY, Mefford HC, et al. BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2. Am J Hum Genet 1997;60:1031.

Friedman LS, Gayther SA, Kurosaki T, et al. Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet 1997;60:313.

Wooster R, Bignell G, Lancaster J. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378:789.

Kozak FK, Hall JG, Baird PA. Familial breast cancer in males. A case report and review of the literature. Cancer 1986;58:2736.

Hauser A, Lemer I, King R. Familial male breast cancer. Am J Med Genet 1992;44:839.

Nemoto TVJ, Bedwani R, Baker HW, McGregor FH, Murphy GP. Management and survival of female breast cancer: results of a national survey by the American College of Physicians. Cancer 1980,45:2917.

Wooster R, Mangion J, Eeles R, et al. A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome. Nat Genet 1992;2:132.

Lobaccaro J, Lumbroso S, Belon C, et al. Male breast cancer and the androgen receptor gene [Letter]. Nat Genet 1993;5:109.

Teng DH, Bogden R, Mitchell J, et al. Low incidence of BRCA2 mutations in breast carcinoma and other cancers . Nat Genet 1996;113:241.

Phelan CM, Lancaster JM, Tonin P, et al. Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nat Genet 1996;13:120.

Shih K, Antin-Ozerkis D, Nathanson K, Rebbeck T, Weber B. Multiple primary cancers are associated with BRCA1 or BRCA2 mutations. Am J Hum Genet 1998;63[Suppl 4]:A86.

Neuhausen S, Gilewski T, Norton L, et al. Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nat Genet 1996;13:126.

Lancaster JM, Wooster R, Mangion J, et al. BRCA2 mutations in primary breast and ovarian cancers. Nat Genet 1996;13:238.

Miki Y, Katagiri T, Kasumi F, Yoshimoto T, Nakamura Y. Mutation analysis in the BRCA2 gene in primary breast cancers. Nat Genet 1996;13:245.

Takahashi K, Chiu HC, Bandera CA, et al. Mutations of the BRCA2 gene in ovarian carcinomas. Cancer Res 1996;56:2738.

Tonin P, Weber B, Offit K, et al. Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med 1996;2:1179.

Gudmundsson J, Johannesdottir G, Arason A, et al. Frequent occurrence of BRCA2 linkage in Icelandic breast cancer families and segregation of a common BRCA2 haplotype. Am J Hum Genet 1996;58:749.

Neuhausen SL, Godwin AK, Gershoni-Baruch R, et al. Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study. Am J Hum Genet 1998;62:1381.

Chen J, Silver D, Walpita D, et al. Stable interaction between products of BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. Molecular Cell 1998;2:317.

Rajan JV, Wang M, Marquis ST, Chodosh LA. Brca2 is coordinately regulated with Brca1 during proliferation and differentiation in mammary epithelial cells. Proc Natl Acad Sci U S A 1996;93:13078.

Bertwistle D, Swift S, Marston NJ, et al. Nuclear location and cell cycle regulation of the BRCA2 protein. Cancer Res 1997;57:5485.

Milner J, Ponder B, Hughes-Davies L, Seltmann M, Kouzarides T. Transcriptional activation functions in BRCA2. Nature 1997;386:772.

Wong AKC, Pero R, Ormonde PA, Tavtigian SV, Bartel PL. RAD51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene brca2. J Biol Chem 1997;272:31941.

Mizuta R, LaSalle JM, Cheng HL, et al. RAB22 and RAB163/mouse BRCA2: proteins that specifically interact with the RAD51 protein. Proc Natl Acad Sci U S A 1997;94:6927.

Rajan TV, Marquis ST, Gardner HP, Chodosh LA. Developmental expression of Brca2 colocalizes with Brca1 and is associated with proliferation and differentiation in multiple tissues. Dev Biol 1997;1184:385.

Sharan SK, Morimatsu M, Albrecht U, et al. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 1997;386:804.

Suzuki A, de la Pompa JL, Hakem R, et al. Brca2 is required for embryonic cellular proliferation in the mouse. Genes Dev 1997;511:1242.

Friedman LS, Thistlethwaite FC, Patel KJ, et al. Thymic lymphomas in mice with a truncating mutation in Brca2. Cancer Res 1998;58:1338.

Connor F, Bertwistle D, Mee PJ, et al. Tumorigenesis and a DNA repair defect in mice with a truncating Brca2 mutation. Nat Genet 1997; 17:423.

Gudas JM, Li T, Nguyen H, Jensen D, Rauscher FJ, Cowan KH. Cell cycle regulation of BRCA1 messenger RNA in human breast epithelial cells. Cell Growth Differ 1996;7:717.

Lim DS, Hasty P. A mutation in mouse rad5l results in an early embryonic lethal that is suppressed by a mutation in p53. Mol Cell Biol 1996;16:7133.

Morimatsu M, Donoho G, Hasty P. Cells deleted for Brca2 COOH terminus exhibit hypersensitivity to gamma-radiation and premature senescence. Cancer Res 1998;58:3441.

McAllister KA, Haugen-Strano A, Hagevik S, et al. Characterization of the rat and mouse homologues of the BRCA2 breast cancer susceptibility gene. Cancer Res 1997;57:3121.

Patel KJ, Vu VP, Lee K, et al. Involvement of Brca2 in DNA repair. J Clin Monit Comput 1998;1:347.

Abbott DW, Freeman ML, Holt JT. Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells. J Natl Cancer Inst 1998;90:978.

Li FP, Fraumeni JF. Soft-tissue sarcomas, breast cancer, and other neoplasms: familial syndrome? Ann Intern Med 1969;71:747.

Li FP, Fraumeni JF, Mulvihill JJ. A cancer family syndrome in 24 kindreds. Cancer Res 1988;48:5358.

Strong LC, Williams WR, Tainsky MA. The Li-Fraumeni syndrome: from clinical epidemiology to molecular genetics. Am J Epidemiol 1992;135:190.

Williams W, Strong L. Genetic epidemiology of soft tissue sarcomas in children. In: Muller H, Weber W, eds. Familial cancer: first international research conference. Basel, Switzerland: Karger, 1985:151.

Garber JE, Goldstein AM, Kantor AF, Dreyfus MG, Fraumeni JF Jr, Li FP. Follow-up study of twenty-four families with Li-Fraumeni syndrome. Cancer Res 1991;51:6094.

Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990;250:1233.

Srivasta S, Zou ZQ, Pirollo K, Blattner W, Chang EH. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 1990;348:747.

Frebourg T, Kassel J, Lam KT, et al. Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein. Proc Natl Acad Sci U S A 1992;89:6413.

Bames DM, Hanby AM, Gillett CE, et al. Abnormal expression of wild type p53 protein in normal cells of a cancer family patient. Lancet 1992;340:259.

Toguchida J, Yamaguchi T, Dayton SK, et al. Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma. N Engl J Med 1992;326:1301.

Sidransky D, Tokino T, Helzlsouer K, et al. Inherited p53 gene mutations in breast cancer. Cancer Res 1992;52:2984.

Borresen AL, Andersen TI, Garber J, et al. Screening for germ line TP53 mutations in breast cancer patients. Cancer Res 1992;52:3234.

Savitsky K, Sfez S, Tagle DA, et al. The complete sequence of the coding region of the ATM gene reveals similarity to cell cycle regulators in different species. Hum Mol Genet 1995;14:2025.

Swift M, Reltnauer PJ, Morrell D, Chase CL. Breast and other cancers in families with ataxia-telangiectasia. N Engl J Med 1987; 316:1289.

Swift M, Morrell D, Massey RB, Chase CL. Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 1991;325:1831.

Easton DF. Cancer risks in A-T heterozygotes. Int J Radiat Biol 1994;66[Suppl 6]:S177.

Athma P, Rappaport R, Swift M. Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet Cytogenet 1996;92:1304.

Vorechovsky I, Rasio D, Luo L, et al. The ATM gene and susceptibility to breast cancer: analysis of 38 breast tumors reveals no evidence for mutation. Cancer Res 1996;56:2726.

Chen J, Birkholtz GG, Lindblom P, Rubio C, Lindblom A. The role of ataxia-telangiectasia heterozygotes in familial breast cancer. Cancer Res 1998;58:1376.

Fitzgerald MG, Bean JM, Hegde SR, et al. Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nat Genet 1997;15:307.

Brownstein MH, Wolf M, Bikowski JB. Cowden's disease: a cutaneous marker of breast cancer. Cancer 1978;41:2393.

Starink TM. Cowden's disease: analysis of fourteen new cases. J Am Acad Dermatol 1984;11:1127.

Nelen MR, Padberg GW, Peeters EA, et al. Localization of the gene for Cowden disease to chromosome 10q22-23. Nat Genet 1996;13:114.

Liaw D, Marsh DJ, Li J, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997;16:64.

Nelen MR, van Staveren WC, Peeters EA, et al. Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Hum Mol Genet 1997;6:1383.

Tsou HC, Teng DH, Ping XL, et al. The role of MMAC1 mutations in early-onset breast cancer: causative in association with Cowden syndrome and excluded in BRCA1-negative cases. Am J Hum Genet 1997;61:1036.

Li DM, Sun H. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res 1997;57:2124.

Jeghers K, McKusick V, Katz K. Generalized intestinal polyposis and melanin spots of the oral mucosa, lips and digits: a syndrome of diagnostic significance. N Engl J Med 1949;241:992.

Peutz J. On a very remarkable case of familial polyposis of the mucous membrane of the intestinal tract and nasopharynx accompanied by peculiar pigmentation of the skin and mucous membrane. Ned Tijdschr Geneeskd 1921;110:134.

Giardiello FM, Welsh SB, Hamilton SR, et al. Increased risk of cancer in the Peutz-Jeghers syndrome. N Engl J Med 1987;316:1511.

Boardman LA, Thibodeau SN, Schaid DJ, et al. Increased risk for cancer in patients with the Peutz-Jeghers syndrome. Ann Intern Med 1998;128:896.

Hemminki A, Tomlinson I, Markie D. Localization of a susceptibility locus for PJS to 19p using comparative genomic hybridization and targeted linkage analysis. Nat Genet 1997;115:87.

Olschwang S, Markle D. Peutz-Jeghers disease: most, but not all, families are compatible with linkage to 19p13.3 . J Med Genet 1998;35:42.

Muir EG, Bell AJ, Barlow KA. Multiple primary carcinomata of the colon, duodenum, and larynx associated with kerato-acanthomata of the face. Br J Surg 1967;54:191.

Hall NR, Williams MA, Murday VA, Newton JA, Bishop DT. Muir-Torre syndrome: a variant of the cancer family syndrome. J Med Genet 1994;31:627.

Anderson DE. An inherited form of large bowel cancer: Muir's syndrome. Cancer 1980;45[Suppl 5]:1103.

Fishel R, Lescoe MK, Rao MR, et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer [Published erratum appears in Cell 1994;77:167]. Cell 1993;75:1027.

Leach FS, Nicolaides NC, Papadopoulos N, et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer . Cell 1993;75:1215.

Papadopoulos N, Nicolaides NC, Wei YF, et al. Mutation of a mutL homolog in hereditary colon cancer. Science 1994;263:1625.

Bronner CE, Baker SM, Morrison PT, et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 1994;368:258.

Kolodner PD, Hall NR, Lipford J, et al. Structure of the human MSH2 locus and analysis of two Muir-Torre kindreds for msh2 mutations [Published erratum appears in Genomics 1995;28:613]. Genomics 1994;24:516.

Bapat B, Xia L, Madlensky L, et al. The genetic basis of Muir-Torre syndrome includes the hMH1 locus [Letter]. Am J Hum Genet 1996;59:736.